12/5
06:37 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/5
06:00 pm
nktr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26
09:11 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.
11/24
07:02 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
11/19
07:43 pm
nktr
How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]
Medium
Report
How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]
11/16
01:10 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) was downgraded by analysts at
Wall Str
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) was downgraded by analysts at
Wall Str
11/12
11:02 am
nktr
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets [Seeking Alpha]
Low
Report
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets [Seeking Alpha]
11/12
12:41 am
nktr
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout [Seeking Alpha]
Low
Report
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout [Seeking Alpha]
11/8
06:32 pm
nktr
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting [Yahoo! Finance]
Low
Report
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting [Yahoo! Finance]
11/8
05:45 pm
nktr
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Low
Report
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
11/8
12:52 pm
nktr
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
Low
Report
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
11/6
04:36 pm
nktr
Nektar Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Nektar Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/6
04:15 pm
nktr
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
Medium
Report
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
10/30
06:00 pm
nktr
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Medium
Report
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
10/28
06:00 pm
nktr
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
Low
Report
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
10/22
08:00 am
nktr
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Low
Report
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
10/14
08:39 am
nktr
FDA Fast Track for Eczema Therapy Could Be a Game Changer for Nektar Therapeutics (NKTR) [Yahoo! Finance]
Low
Report
FDA Fast Track for Eczema Therapy Could Be a Game Changer for Nektar Therapeutics (NKTR) [Yahoo! Finance]
10/13
09:07 am
nktr
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street [Yahoo! Finance]
Low
Report
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street [Yahoo! Finance]
10/8
12:30 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/5
09:11 am
nktr
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September [Yahoo! Finance]
Low
Report
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September [Yahoo! Finance]
9/23
02:23 pm
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at B. Riley from $85.00 to $105.00. They now have a "buy" rating on the stock.
Low
Report
Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at B. Riley from $85.00 to $105.00. They now have a "buy" rating on the stock.
9/21
07:09 pm
nktr
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? [Yahoo! Finance]
Medium
Report
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? [Yahoo! Finance]
9/20
08:17 am
nktr
How Recent Breakthroughs Are Changing the Nektar Therapeutics Investment Story [Yahoo! Finance]
Medium
Report
How Recent Breakthroughs Are Changing the Nektar Therapeutics Investment Story [Yahoo! Finance]
9/19
11:32 pm
nktr
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today [Yahoo! Finance]
Medium
Report
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today [Yahoo! Finance]
9/19
08:07 am
nktr
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $100.00 price target on the stock.
Medium
Report
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $100.00 price target on the stock.